42623

Butyryl-L-carnitine

≥97.0% (TLC)

• Synonim(y): (2R)-3-Carboxy-N,N,N-trimethyl-2-(1-oxobutoxy)-1-propanaminium inner salt, Butanoyl-L-carnitine, C4-Carnitine
• Wzór empiryczny (zapis Hilla): C₁₁H₂₁NO₄
• Numer CAS: 25576-40-3
• Masa cząsteczkowa: 231.29
• UNSPSC Code: 41116107
• PubChem Substance ID: 329756249
• NACRES: NA.26
• MDL number: MFCD01674827

Właściwości

• Nazwa produktu: Butyryl-L-carnitine, ≥97.0% (TLC)
• Quality Segment: 100
• assay: ≥97.0% (TLC)
• form: powder, crystals or chunks
• optical activity: [α]/D -23±2°, c = 1 in H₂O
• color: white to off-white
• storage temp.: 2-8°C
• SMILES string: C[N+](C)(C)C[C@H](OC(CCC)=O)CC([O-])=O
• InChI: 1S/C11H21NO4/c1-5-6-11(15)16-9(7-10(13)14)8-12(2,3)4/h9H,5-8H2,1-4H3/t9-/m1/s1
• InChI key: QWYFHHGCZUCMBN-SECBINFHSA-N

Opis

Application

• Lead exposure induces metabolic reprogramming in rat models.: This study by Mani MS et al. investigates the metabolic effects of lead exposure in rat models, focusing on the biochemical pathways affected. The research highlights the role of butyryl-ʟ-carnitine in counteracting lead-induced metabolic disruptions, suggesting its potential therapeutic applications in mitigating heavy metal toxicity (Mani et al., 2020).

Biochem/physiol Actions

Butyrylcarnitine is elevated in patients with Acyl-CoA dehydrogenase, short-chain (SCAD) deficiency, in infants with acute acidosis and generalized muscle weakness and in middle-aged patients with chronic myopathy localized in muscle[1][2][3]; very long chain Acyl-CoA dehydrogenase deficiency[4], and celiac disease[5].

Ta strona może zawierać tekst przetłumaczony maszynowo.

Informacja o środkach bezpieczeństwa

• Klasa składowania: 11 - Combustible Solids
• flash_point_f: Not applicable
• flash_point_c: Not applicable